Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ObsEva Ord Shs OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Annual General Meeting 2021

GlobeNewswire April 22, 2021

ObsEva Announces Year End 2020 Financial Results and Business Update

GlobeNewswire March 5, 2021

ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 3, 2021

ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

GlobeNewswire February 17, 2021

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

GlobeNewswire February 11, 2021

ObsEva Provides Business Outlook for 2021

GlobeNewswire February 10, 2021

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

GlobeNewswire January 28, 2021

ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program

GlobeNewswire January 11, 2021

ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 - 14, 2021

GlobeNewswire January 7, 2021

ObsEva appoints David Renas as Chief Financial Officer

GlobeNewswire January 4, 2021

ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

GlobeNewswire December 10, 2020

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress - virtual edition, December 2-5, 2020

GlobeNewswire December 1, 2020

ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids

GlobeNewswire November 24, 2020

ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

GlobeNewswire November 16, 2020

ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 - 19, 2020

GlobeNewswire November 13, 2020

ObsEva appoints Brian O'Callaghan as Chief Executive Officer

GlobeNewswire November 9, 2020

ObsEva Announces Third Quarter 2020 Financial Results and Business Update

GlobeNewswire November 5, 2020

ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020

GlobeNewswire November 2, 2020

ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21

GlobeNewswire October 22, 2020

ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21

GlobeNewswire October 20, 2020